1.
Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica [Internet]. 2004May1 [cited 2026Nov.19];89(5):520-7. Available from: https://haematologica.org/article/view/3073